TB-500 Thymosin Beta-4 Research: Actin Dynamics in Inflammatory Cell Models

TB-500 Thymosin Beta-4 Research: Actin Dynamics in Inflammatory Cell Models

TB-500 is a research compound studied in cell-based assay formats for its G-actin sequestration, ILK-integrin signalling, and cytoskeletal actin dynamics. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.

Receptor Pharmacology and Mechanism of Action

Primary Binding Targets

TB-500 demonstrates high-affinity binding interactions with monomeric G-actin through its central actin-binding domain. Competitive radioligand binding assays reveal nanomolar binding constants (Kd ~50-100 nM) for G-actin sequestration in purified protein systems. The compound exhibits selective binding to the ATP-bound form of actin monomers, preventing their incorporation into filamentous F-actin structures.

Surface plasmon resonance studies indicate direct binding interactions between TB-500 and integrin-linked kinase (ILK) complexes, with measured association rates suggesting physiologically relevant binding kinetics. The binding interface involves specific amino acid residues within the thymosin beta-4 sequence that mediate conformational changes in target protein structures.

Cytoskeletal Signalling Pathways

TB-500 modulates multiple actin-regulatory pathways through its sequestration mechanism. In fibroblast cell models, the compound demonstrates dose-dependent effects on cofilin phosphorylation status via LIMK1/2 pathway modulation. Fluorescence microscopy analysis reveals altered stress fiber formation and focal adhesion dynamics following TB-500 exposure in concentrations ranging from 10-100 μM.

Integrin-linked kinase signalling represents a secondary pathway influenced by TB-500 binding interactions. The compound affects downstream Akt/PKB phosphorylation cascades in endothelial cell models, with measurable changes in kinase activity observed through in vitro kinase assays. Time-course studies indicate rapid onset effects within 15-30 minutes of compound addition.

In Vitro Inflammatory Response Models

NF-κB Pathway Modulation

Cell-based reporter assays using NF-κB-luciferase constructs demonstrate TB-500's capacity to modulate inflammatory signalling cascades. The compound exhibits concentration-dependent inhibition of TNF-α-induced NF-κB activation in HEK293 and primary macrophage cell models. IC50 values for NF-κB inhibition range from 25-75 μM depending on cell type and stimulation conditions.

Western blot analysis reveals TB-500's effects on IκB-α degradation kinetics and p65 nuclear translocation in activated inflammatory cell models. The compound appears to influence upstream regulatory mechanisms rather than direct transcription factor binding, as confirmed through electrophoretic mobility shift assays.

Cytokine Expression Profiling

Quantitative PCR analysis in lipopolysaccharide-stimulated macrophage cultures shows TB-500-mediated reduction in pro-inflammatory cytokine mRNA expression. The compound demonstrates particular efficacy against IL-1β, IL-6, and TNF-α transcript levels, with peak inhibitory effects observed at 50-100 μM concentrations.

Enzyme-linked immunosorbent assays measuring secreted cytokine levels confirm transcriptional findings, with TB-500 treatment resulting in 40-60% reduction in inflammatory mediator release from activated immune cell models.

Cellular Migration and Adhesion Assays

Transwell Migration Studies

Modified Boyden chamber assays reveal TB-500's influence on cellular migration patterns in multiple cell types. The compound demonstrates biphasic effects, with low concentrations (1-10 μM) enhancing migration while higher concentrations (>50 μM) show inhibitory properties. These effects correlate with actin polymerization states measured through phalloidin staining protocols.

Focal Adhesion Dynamics

Live-cell imaging studies using fluorescently-tagged focal adhesion proteins demonstrate TB-500's effects on adhesion complex turnover rates. The compound alters vinculin and paxillin localization patterns, with measurable changes in focal adhesion lifetime and size distribution observed through automated image analysis.

Research Summary

TB-500 represents a valuable research tool for investigating actin cytoskeleton regulation and inflammatory pathway modulation in controlled cell culture systems. Its dual mechanism involving G-actin sequestration and integrin-linked kinase interactions provides researchers with opportunities to dissect complex cellular processes. The compound's effects on NF-κB signalling pathways and cytokine expression profiles make it particularly relevant for inflammatory response studies. Current in vitro data support concentrations of 10-100 μM for most cell-based assays, with specific applications requiring optimization based on target pathway and cell model characteristics.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML